To develop and provide life-enhancing products and technologies with a commitment to quality as the goal at every step of the process.
Hancock Jaffe Laboratories develops life-enhancing bioprosthetic devices and technologies intended to achieve unparalleled outcomes for patients with debilitating cardiovascular diseases. Each device is designed to allow vascular and cardiothoracic surgeons to achieve maximum effectiveness while greatly reducing the time and complexity of current procedures in concert with a commitment to efficient health care delivery.
Venous Valve: Remarkably Mimetic of a Native Venous Valve
Bioprosthetic venous valve designed to provide surgeons with the first comprehensive surgical option for the treatment of lower limb chronic deep venous insufficiency, recognized as one of the most disabling and debilitating conditions in the United States and Europe.
Heart Valve: Specifically Designed to Simulate Pediatric and Adolescent Native Heart Valves
Bioprosthetic heart valve replacement is especially designed to meet the demands of the pediatric and adolescent patient. The design incorporates patented features that optimize performance and durability with the benefit of the widely recognized lack of need for anti-coagulation therapy. Hemodynamic preclinical studies provide evidence that the bioprosthesis has significant potential to greatly reduce the number of procedures commonly required as patients grow and approach adulthood.
CoreoGraft™ – Coronary Artery Bypass Graft: Anatomically and Functionally Mimetic of Free Saphenous Vein Grafts
Bioprosthetic coronary artery bypass graft is specifically designed to address the unique demands of coronary artery blood flow. The “off the shelf” CoreoGraftTM bioprosthesis will allow for more complete revascularization of the diseased heart with the goal of eliminating the need for vein and artery harvesting procedures thus greatly reducing the comorbidities and complications attendant to graft harvesting.
ProCol® Vascular Bioprosthesis for Hemodialysis Access: Provides Improved Patency Compared with ePTFE Grafts
The ProCol® Vascular Bioprosthesis was approved by the U.S. Food and Drug Administration in 2003 and is intended for the creation of a bridge graft for vascular access subsequent to at least one previously failed prosthetic access graft. This bioprosthetic graft has been shown in clinical studies both in Europe and the United States to provide end-stage renal disease patients with a viable access option. The ProCol® bioprosthesis is a natural biological graft derived from a bovine mesenteric vein. The manufacturing and sterilization process ensures a product that is flexible, easy to suture and which exhibits physiologic pulsatile flow characteristics similar to a native fistula. For additional information about the ProCol® Vascular Bioprosthesis, please click the Learn More button below. Note, this will take you off this site.